Navigation Links
Yondelis(R) Sales Expanded by 70 Percent
Date:10/28/2010

MADRID, Oct. 28 /PRNewswire/ -- Group revenues totaled 120 million euro (approximately 167 million USD*) in the first nine months of 2010, i.e. an increase of 26.1 percent with respect to the same period last year (95.19 million euro or approximately 132.6 million USD).

Net sales in the Biopharmaceutical business amounted to 56.9 million euro or approximately 79.3 million USD (35.8 million euro or approximately 49.9 million USD in the first nine months of 2009), of which 51.8 million (approximately 72.1 million USD) correspond to Yondelis sales (30.4 million euro or approximately 42.3 million USD in 9M09). Genomica's sales totaled 5.1 million euro (approximately 7.1 million USD).

The Consumer chemicals division reported sales of 62.2 million euro or approximately 86.6 million USD (58.6 million euro or approximately 81.6 million USD in 9M09). This division accounted for 51.8 percent of total group revenues in the first nine months of 2010 (61.5 percent in 9M09).

The Group maintained positive EBITDA of 2.7 million euro (approximately 3.8 million USD) in 9M10, driven by steadily rising sales since the beginning of the year.

Net income attributable to the parent company improved 63 percent with respect to September 2009.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two profitable companies that are leaders in their respective market segments.

For more information, Zeltia +34 91 444 4500

This note is also available at Zeltia's web site: www.zeltia.com

* All original figures are in Euros; dollar figures are estimated using the exchange rate: 1.3928.


'/>"/>
SOURCE Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
2. Decision Resources Forecast of Global Tanezumab Sales Slashed Following FDA Halt of Phase III Studies
3. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
4. Assured Pharmacy Reports Same Store Sales for the Month of September 2010
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
6. Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010
7. Reportlinker Adds Sales Force Effectiveness in Pharmaceuticals - Cost Pressures Increase Pharmaceutical Companies Adoption of New Sales Models and Technologies
8. Gerresheimer Reports Strong Earnings and Sales Growth
9. Nonin Medical, Inc. Announces Capnography Division Name Change; Expands Swedish Manufacturing Facility to Become Full-Franchise European Sales, Distribution and Service Center
10. Health Strategies Group Introduces New One-Stop Suite of Intelligence Services for Optimizing Marketing and Sales Resources in the Institutional Channel
11. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- Sanovas, Inc., a life science asset holding ... its wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed ... - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed ...
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 /PRNewswire/ ... announced preliminary safety and efficacy data from a ... selective MDM2 inhibitor, suggesting that DS-3032 may be ... acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome ... of the phase 1 study of DS-3032 were presented ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... The ... care facility – Avamere Transitional Care of Puget Sound ; located at ... health care center will provide patients recovering from illness or injury with intensive ...
(Date:12/5/2016)... VA (PRWEB) , ... December 05, 2016 , ... ... today announced it has been featured in SuperbCrew magazine, a leading online tech ... tech world. This interview, now featured on SuperbCrew.com, explores the state of enterprise ...
(Date:12/5/2016)... ... ... Researchers at Johns Hopkins All Children’s Hospital want to learn more about ... of three years, researchers will study concussions and changes in brain function by monitoring ... sensors, will track the location and force of the hit. The sensors store data ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy ... through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the ... 26 people will be diagnosed with epilepsy within their lifetime. With such a ...
Breaking Medicine News(10 mins):